Dr. Irene K. Kim, MD

Dr. Kim practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Kim's NPI, 1932390390, was assigned on August 9, 2007. Dr. Kim graduated from UCSF School of Medicine in 2004. Dr. Kim holds California license A111330.

Dr. Kim's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Kim's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Kim to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kim practices, 2 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Kim's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Kim is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Kim's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists kidney transplant among the conditions Dr. Kim treats.

CMS data shows 135 Medicare services from Dr. Kim across 4 procedure codes in 2024, for 60 Medicare patients. Medicare paid $65,094 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 60 Medicare patients who saw Dr. Kim in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 47% are also on Medicaid. Their average risk score is 8.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kim's median patient age at 63, with 44% women.

In 2024, Dr. Kim wrote 352 Medicare Part D claims for 23 patients. 76% of them were for generic drugs. CMS names the drug for 222 of them, across 8 drugs with 11 or more claims each, at $5,494 in total drug cost. In 2023, CMS named 74 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Kim for performance year 2024, reported as part of a group. Dr. Kim accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 33 papers to Dr. Kim, published from 2010 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Graft Survival, Kidney Transplantation and Liver Transplantation. Dr. Kim has published most often in Pediatr Transplant. Dr. Kim's most frequent co-authors are Justin A. Steggerda, MD, Steven Andrew Wisel, MD and Tsuyoshi Todo, MD.

CMS Open Payments shows 93 general payments to Dr. Kim from 22 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 61% of the total. Sanofi and Genzyme US Companies paid the most, $17,891.

Dmand AI lists 10 awards for Dr. Kim, most recently Poster of Distinction in 2013.

Dr. Kim graduated from UCSF School of Medicine in 2004. Dr. Kim is a member of ACS, American Society of Transplantation, American Society of Transplant Surgeons, AAS, International Liver Transplant Society and Society of University Surgeons.

Dr. Kim is in network with 13 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.